Noveome Biotherapeutics, Inc. Announces New Appointments to Board of Directors
and Houman D. Hemmati, M.D., Ph.D. to the companys Board of Directors.
- and Houman D. Hemmati, M.D., Ph.D. to the companys Board of Directors.
- Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies.
- We are delighted to welcome Eric and Houman to our Board of Directors.
- Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs).